Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Netherlands Heart Journal
Gepubliceerd in:

01-01-2007 | Satellite symposia

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

Vienna, 4 September 2007

Auteur: M. V. Huisman

Gepubliceerd in: Netherlands Heart Journal | Uitgave 1/2007

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Extract

Patients with type 2 diabetes are at increased risk of both macrovascular disease, including coronary heart disease and stroke, and microvascular disease, which includes retinopathy and nephropathy. Blood pressure and glucose levels are important determinants of the risk of developing vascular disease in patients with diabetes. For both these risk factors, the associations with macrovascular and microvascular disease appear continuous, with no evidence of a lower level of blood pressure or haemoglobin A1c below which the risks do not continue to decline. …
vorige artikel New evidence in the management of cardiovascular risk: the place of heart rate
volgende artikel Innovative device technologies for optimised heart failure management
Metagegevens
Titel
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
Vienna, 4 September 2007
Auteur
M. V. Huisman
Publicatiedatum
01-01-2007
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 1/2007
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086059

Andere artikelen Uitgave 1/2007

Past, present and future of ACE inhibitors

  • Satellite symposia

Highlight session

  • Highlight session

New evidence in the management of cardiovascular risk: the place of heart rate

  • Satellite symposia

If inhibition: the new strategy in cardiovascular risk management

  • Satellite symposia

Hot line II

  • Hot lines

The bridge to achieving the greater LDL-C goal of <70 mg/dl: inhibiting cholesterol absorption and production

  • Satellite symposia